China · Delayed Price · Currency is CNY BGI Genomics Statistics
Total Valuation
BGI Genomics has a market cap or net worth of CNY 14.61 billion. The enterprise value is 12.28 billion.
| Market Cap | 14.61B |
| Enterprise Value | 12.28B |
Important Dates
The last earnings date was Saturday, October 24, 2026.
| Earnings Date | Oct 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BGI Genomics has 383.85 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 383.85M |
| Shares Outstanding | 383.85M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -2.67% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 12.78% |
| Float | 221.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 136.74 |
| PS Ratio | 3.81 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 53.11 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.18 |
| EV / EBITDA | 125.51 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.83, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.83 |
| Quick Ratio | 2.49 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 7.64 |
| Debt / FCF | n/a |
| Interest Coverage | -12.75 |
Financial Efficiency
Return on equity (ROE) is -6.34% and return on invested capital (ROIC) is -7.03%.
| Return on Equity (ROE) | -6.34% |
| Return on Assets (ROA) | -2.23% |
| Return on Invested Capital (ROIC) | -7.03% |
| Return on Capital Employed (ROCE) | -4.59% |
| Weighted Average Cost of Capital (WACC) | 8.18% |
| Revenue Per Employee | 1.04M |
| Profits Per Employee | -152,236 |
| Employee Count | 3,580 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 4.75 |
Taxes
In the past 12 months, BGI Genomics has paid 66.02 million in taxes.
| Income Tax | 66.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.61% in the last 52 weeks. The beta is 0.76, so BGI Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -23.61% |
| 50-Day Moving Average | 40.23 |
| 200-Day Moving Average | 41.38 |
| Relative Strength Index (RSI) | 39.45 |
| Average Volume (20 Days) | 11,955,753 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BGI Genomics had revenue of CNY 3.72 billion and -545.01 million in losses. Loss per share was -1.31.
| Revenue | 3.72B |
| Gross Profit | 1.21B |
| Operating Income | -418.25M |
| Pretax Income | -495.68M |
| Net Income | -545.01M |
| EBITDA | 60.82M |
| EBIT | -418.25M |
| Loss Per Share | -1.31 |
Balance Sheet
The company has 3.16 billion in cash and 720.76 million in debt, with a net cash position of 2.44 billion or 6.36 per share.
| Cash & Cash Equivalents | 3.16B |
| Total Debt | 720.76M |
| Net Cash | 2.44B |
| Net Cash Per Share | 6.36 |
| Equity (Book Value) | 8.35B |
| Book Value Per Share | 20.11 |
| Working Capital | 3.66B |
Cash Flow
In the last 12 months, operating cash flow was 266.82 million and capital expenditures -550.18 million, giving a free cash flow of -283.37 million.
| Operating Cash Flow | 266.82M |
| Capital Expenditures | -550.18M |
| Depreciation & Amortization | 479.07M |
| Net Borrowing | 81.98M |
| Free Cash Flow | -283.37M |
| FCF Per Share | -0.74 |
Margins
Gross margin is 32.56%, with operating and profit margins of -11.23% and -14.64%.
| Gross Margin | 32.56% |
| Operating Margin | -11.23% |
| Pretax Margin | -13.31% |
| Profit Margin | -14.64% |
| EBITDA Margin | 1.63% |
| EBIT Margin | -11.23% |
| FCF Margin | n/a |
Dividends & Yields
BGI Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | -3.44% |
| FCF Yield | -2.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BGI Genomics has an Altman Z-Score of 4.6 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.6 |
| Piotroski F-Score | 4 |